Notice for International Patients & Caregivers

English summary does not mean the trial enrolls international patients. Multiple myeloma interventional clinical trials in China typically require valid Chinese resident identity/national healthcare insurance and strict adherence to China's Human Genetic Resources Administration regulations.

Provincial Landscape

Snapshot: 2026-10-21

Hunan Multiple Myeloma Active Trials & Centers

As of 2026-10-21, there are 23 active clinical trials for multiple myeloma hosted across 9 tertiary medical centers in Hunan (including Hunan Cancer Hospital, Chenzhou No. 1 People's Hospital, The Second Xiangya Hospital of Central South University, etc.).

Active Trials

Hospitals

Therapies

CAR-T Cell Therapy / Bispecific & Multispecific Antibodies / Monoclonal Antibodies / Oral Small-Molecule Agents

Participating Medical Centers (9)

Hunan Cancer HospitalChenzhou No. 1 People's HospitalThe Second Xiangya Hospital of Central South UniversityThe Third Xiangya Hospital of Central South UniversityXiangya Hospital, Central South UniversityLoudi Central HospitalThe First People's Hospital of ChangdeZhuzhou Central HospitalThe First Hospital of University of South China

Active Studies in Hunan (23)

Population synthesized by CMDN

Showing 0 published English records of 23 registry trials.

All 23 local registry studies currently have Chinese-only filings. Verified English summaries will be published upon regulatory audit.

Back to National Landscape Filter Local Trials in the Trial Hub